First-half sales at Ipsen increase 18.8%

27 July 2017

French specialty pharma group Ipsen (Euronext: IPN) today announced financial results for the first half of 2017, reporting strong operating performance.

Group sales grew 18.8% to 919.5 million euros ($978 million) and core operating income margin improvement by 1.2 points to 26.2% of sales. Core operating income was up 25.7% at 240.5 million euros and core consolidate net profit was 169.2 million, a rise of 16.2%, resulting in core earnings per share of 2.04 euros, up 15.7%.

· Specialty Care sales growth of 23.1% to 764.6 million euros reflects continued Somatuline (lanreotide) momentum and includes contribution of key new products Cabometyx (cabozantinib) and Onivyde (irinotecan).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK